Libido, sex drive, Viagra
Libido, sex drive, Viagra


PMS: What can be done about my decreased libido (sex drive)?

Home
What's New - Blog
Abortion
Amenorrhoea - Absent Periods
Birth Control
Bladder Symptoms
Cancer in Women
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometriosis
Female Sexual Problems
Fibroids
HRT Risks & Benefits
Hysterectomy
Infections
Infertility
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Miscarriage
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Vaginal Discharge
Vaginal Prolapse
Viagra, Libido and Sex Drive.
The Author
Consultations
Contact Us

J Womens Health Gend Based Med. 2002 May;11(4):367-77.

Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.

Basson R,McInnes R,Smith MD,Hodgson G,Koppiker N.

Vancouver Hospital and Health Sciences Center, British Columbia, Canada.

Objectives:

Sildenafil citrate (Viagra Pfizer, New York, NY) is indicated for the treatment of erectile dysfunction in men. The nitric oxide-cyclic guanosine monophosphate pathway (NO-cGMP) involved in penile erection and enhanced by sildenafil may also play a role in some components of the female sexual arousal response. The efficacy and safety of sildenafil were evaluated in estrogenized and estrogen-deficient women with sexual dysfunction that included female sexual arousal disorder (FSAD).

Methods:

Patients were randomized to receive 10-100 mg sildenafil or matching placebo. To assess efficacy, patients completed two global efficacy questions (GEQ), the Life Satisfaction Checklist (LSC), an event log of sexual activity, and a 31-item sexual function questionnaire (SFQ). To assess safety, adverse event (AE) data were recorded.

Results:

A total of 577 estrogenized and 204 estrogen-deficient women were randomized to treatment. All were diagnosed with FSAD, but it was the primary presenting symptom in only 46% and 50% of women, respectively. Differences in efficacy between sildenafil and placebo were not significant for any patient or partner end points (e.g., the two GEQ, the sexual event logs, the LSC, and the SFQ). The main AE were headache, flushing, rhinitis, nausea, visual disturbances, and dyspepsia, which were generally mild to moderate in nature.

Conclusions:

Any genital physiological effect of sildenafil was not perceived as improving the sexual response in estrogenized or estrogen-deficient women with a broad spectrum of sexual dysfunction that included FSAD. Whether more specific subgroups of women with FSAD could potentially benefit from treatment with sildenafil is an area for future research.

Back Home Up Next

Please click on the required question.

Do you have an unanswered women's health question?

Please let us have your general question on our NEW FORUM / MESSAGE BOARDS facility and we will try to answer it for you. I am sure that you will appreciate that we cannot offer advice on the management of an individual's specific problem.


Thank you for your visiting us at 2WomensHealth.com.

This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.

I do hope that you find the answers to your questions in the patient information and medical advice provided. If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.

DISCLAIMER

The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.

Libido, sex drive, Viagra